The FDA needs to set standards for using artificial intelligence in drug development
Author
Charles K. Fisher
Published
November 7, 2019
Opinion: Poorly constructed AI algorithms for drug discovery and testing have the potential to cause harm. The FDA should play an important role in ensuring that AI-based drug development tools meet appropriate standards.
Part 2: Faster, More Efficient Trials: Novel Trial Designs using Digital Twins
October 21, 2020
Watch an overview of specific use cases for Digital Twins and learn how novel trial designs with Digital Twins enable smaller trials that maintain their power.
Watch a panel discussion on the regulatory landscape where experts share perspectives on the future of AI-based drug development tools like Digital Twins.
